Skip to content
10-Q

Quarterly Report

Bioventus Inc. BVS

0001628280-25-022401

← back to feed
Filed
May 6, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Long Term Debt Q1 2025 · Mar 29, 2025 $308.59M
Long Term Debt Q1 2025 · Dec 31, 2024 $308.29M
Short Term Debt Q1 2025 · Mar 29, 2025 $37.34M
Short Term Debt Q1 2025 · Dec 31, 2024 $27.34M
Cash And Equivalents Q1 2025 · Mar 29, 2025 $22.8M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $41.58M
Stockholders Equity Q1 2025 · Mar 29, 2025 $148.14M
Stockholders Equity Q1 2025 · Dec 31, 2024 $147.94M
Current Liabilities Q1 2025 · Mar 29, 2025 $174.75M
Current Liabilities Q1 2025 · Dec 31, 2024 $210.4M
Total Liabilities Q1 2025 · Mar 29, 2025 $505.94M
Total Liabilities Q1 2025 · Dec 31, 2024 $542.35M
Current Assets Q1 2025 · Mar 29, 2025 $249.37M
Current Assets Q1 2025 · Dec 31, 2024 $275.61M
Total Assets Q1 2025 · Mar 29, 2025 $691.41M
Total Assets Q1 2025 · Dec 31, 2024 $727.96M
Shares Diluted Q1 2025 · Mar 30, 2024 63.38M sh
Capex Q1 2025 · Mar 30, 2024 $291K
Operating Cash Flow Q1 2025 · Mar 30, 2024 −$6.01M
Eps Diluted restated Q1 2025 · Mar 30, 2024 −$0.08
Eps Basic restated Q1 2025 · Mar 30, 2024 −$0.08
Sga Expense restated Q1 2025 · Mar 30, 2024 $78.78M
Rd Expense restated Q1 2025 · Mar 30, 2024 $2.63M
Net Income restated Q1 2025 · Mar 30, 2024 −$4.89M
Operating Income restated Q1 2025 · Mar 30, 2024 $4.93M
Gross Profit Q1 2025 · Mar 30, 2024 $88.38M
Cost Of Revenue Q1 2025 · Mar 30, 2024 $41.08M
Revenue Q1 2025 · Mar 30, 2024 $129.46M